EUVIMEDEUVIMED entdecken
Open Access

Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain

Medizinisches Cannabis und Opioidverordnung bei Erwachsenen mit chronischen Schmerzen

Deepika E Slawek, Chenshu Zhang, Stephen Dahmer, Nancy Sohler, Yuval Zolotov, Joanna L Starrels, Yuting Deng, Giovanna Calderon DiFrancesca, Frances R Levin, Jonathan Ross, Haruka Minami, Chinazo O Cunningham und 1 weitere

JAMA Internal Medicine · 01.02.2026 · 186 (2) · 252

DOI: 10.1001/jamainternmed.2025.6496 ↗

Auf einen Blick

In dieser Kohortenstudie war die Teilnahme am medizinischen Cannabisprogramm in New York State mit geringerem Erhalt verschriebener Opioide über 18 Monate verbunden. Bei 30 Tagen Cannabisversorgung lag die tägliche MME um 3,53 niedriger.

Fragestellung

Besteht bei Erwachsenen mit chronischen Schmerzen ein Zusammenhang zwischen der Teilnahme am medizinischen Cannabisprogramm in New York State und dem Erhalt verschriebener Opioide?

Methode

Kohortenstudie mit Daten des New York State Prescription Monitoring Program von September 2018 bis Juli 2023; Follow-up 18 Monate; Analyse mit marginalen Strukturgleichungsmodellen.

Ergebnisse

204 Teilnehmende. Die mittlere tägliche MME sank von 73,3 auf 57,4. Bei 30 Tagen medizinischem Cannabis waren es 3,53 MME/Tag weniger als ohne Abgabe (β = −3,53; 95 %-KI −6,68 bis −0,04; P = .03).

Schlussfolgerung der Autor:innen

Die Teilnahme am medizinischen Cannabisprogramm in New York State war mit einem geringeren Erhalt verschriebener Opioide während 18 Monaten prospektiver Nachbeobachtung assoziiert, unter Berücksichtigung unregulierten Cannabiskonsums.

Kernaussagen

  • 204 Erwachsene mit chronischen Schmerzen wurden untersucht
  • 30 Tage medizinisches Cannabis: 3,53 MME/Tag weniger
  • Assoziation über 18 Monate prospektiv beobachtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.02.2026. Verfasst von Deepika E Slawek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York. Hauptthemen laut MEDLINE: Medical Marijuana, Chronic Pain, Analgesics, Opioid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Medical cannabis is increasingly considered a substitute for prescription opioid medications for chronic pain, driven by the urgent need for opioid alternatives to combat the ongoing epidemic.

Objective

To determine the association between participation in the New York State (NYS) medical cannabis program and prescription opioid receipt among adults with chronic pain. Design, Setting, and Participants This cohort study used data from the NYS Prescription Monitoring Program (PMP) from September 2018 through July 2023. Adults prescribed opioids for chronic pain who were newly certified for medical cannabis use in NYS were recruited from a large academic medical center and nearby medical cannabis dispensaries in the Bronx, New York. Monthly dispensation of medical cannabis to study participants was monitored for 18 months. Data analyses were performed from February 3, 2025, to July 15, 2025. Exposure Portion of days covered each month by pharmacist report of dispensed medical cannabis. Main Outcomes and Measures Prescription opioid receipt, defined as NYS PMP-reported prescription monthly opioid dispensation (mean daily dose in morphine milliequivalents [MME]), was assessed with marginal structural models adjusted for time-invariant and time-varying confounders, including self-reported unregulated cannabis use. Nonprescribed opioid use was also assessed during the study period.

Results

Among 204 participants, the mean (SD) age at baseline was 56.8 (12.8) years, and 113 (55.4%) were female. At baseline, participants’ mean (SD) pain severity score was 6.6 (1.8) out of 10, and mean (SD) pain interference score was 6.8 (1.9) out of 10. Baseline mean (SD) daily MME was 73.3 (133.0). During the 18-month follow-up period, participants’ mean (SD) daily MME decreased to 57.4 (127.8). This reduction in mean daily MME was associated with the monthly portion of days covered with medical cannabis; compared with no medical cannabis dispensed, participants dispensed a 30-day supply of medical cannabis were exposed to 3.53 fewer MME per day (β = −3.53; 95% CI, −6.68 to −0.04; P = .03). Conclusions and Relevance In this cohort study, participation in NYS’s medical cannabis program was associated with reduced prescription opioid receipt during 18 months of prospective follow-up, accounting for unregulated cannabis use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaChronic PainAnalgesics, OpioidHumansFemaleMaleMiddle AgedNew YorkAdultCohort StudiesAged

Substanzen

Medical MarijuanaAnalgesics, Opioid

Autor:innen und Institutionen

  • Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York.
  • Andrew Weil Center for Integrative Medicine, University of Arizona, Tucson.
  • Department of Community Health and Social Medicine, City University of New York, New York.
  • Department of Health Systems Management, Faculty of Health Sciences, Ariel University, Ariel, Israel.
  • Division on Substance Use Disorders, New York State Psychiatric Institute, New York.
  • Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Slawek, D. E., Zhang, C., Dahmer, S., Sohler, N., Zolotov, Y., Starrels, J. L., Deng, Y., Calderon DiFrancesca, G., Levin, F. R., Ross, J., Minami, H., Cunningham, C. O., & Arnsten, J. H. (2026). Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain. JAMA Internal Medicine, 186(2), 252. https://doi.org/10.1001/jamainternmed.2025.6496

Vancouver

Slawek DE, Zhang C, Dahmer S, Sohler N, Zolotov Y, Starrels JL, et al. Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain. JAMA Internal Medicine. 2026;186(2):252. doi:10.1001/jamainternmed.2025.6496

BibTeX
@article{Slawek2026,
  author = {Slawek, Deepika E and Zhang, Chenshu and Dahmer, Stephen and Sohler, Nancy and Zolotov, Yuval and Starrels, Joanna L and Deng, Yuting and Calderon DiFrancesca, Giovanna and Levin, Frances R and Ross, Jonathan and Minami, Haruka and Cunningham, Chinazo O and Arnsten, Julia H},
  title = {Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {2},
  pages = {252},
  doi = {10.1001/jamainternmed.2025.6496}
}
Kostenlos starten →